tiprankstipranks
Advertisement
Advertisement
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
PremiumThe FlyMicron initiated, Rambus downgraded: Wall Street’s top analyst calls
2M ago
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
Premium
The Fly
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
2M ago
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
Premium
The Fly
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
2M ago
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
PremiumRatingsAnalyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
2M ago
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
Premium
The Fly
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
2M ago
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
Premium
Ratings
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
2M ago
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
PremiumRatingsBuy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
3M ago
Compass Therapeutics reports Q4 EPS (9c), consensus (9c)
Premium
The Fly
Compass Therapeutics reports Q4 EPS (9c), consensus (9c)
4M ago
CMPX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
CMPX Upcoming Earnings Report: What to Expect?
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100